KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EBIT (2016 - 2025)

Historic EBIT for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Amgen's EBIT rose 1769.8% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 billion, marking a year-over-year increase of 2510.33%. This contributed to the annual value of $9.1 billion for FY2025, which is 2510.33% up from last year.
  • Amgen's EBIT amounted to $2.7 billion in Q4 2025, which was up 1769.8% from $2.5 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's EBIT registered a high of $2.7 billion during Q4 2025, and its lowest value of $828.0 million during Q2 2021.
  • For the 5-year period, Amgen's EBIT averaged around $2.1 billion, with its median value being $2.2 billion (2022).
  • As far as peak fluctuations go, Amgen's EBIT plummeted by 6435.64% in 2021, and later soared by 16280.19% in 2022.
  • Over the past 5 years, Amgen's EBIT (Quarter) stood at $2.3 billion in 2021, then dropped by 3.21% to $2.2 billion in 2022, then tumbled by 43.0% to $1.3 billion in 2023, then skyrocketed by 81.83% to $2.3 billion in 2024, then rose by 17.7% to $2.7 billion in 2025.
  • Its EBIT stands at $2.7 billion for Q4 2025, versus $2.5 billion for Q3 2025 and $2.7 billion for Q2 2025.